Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) and Brewer Sports International hosted the 2nd Annual #C4CT Concussion Awareness Summit on January 29th, 2014 at the United Nations. The Summit, taking place in the week before Super Bowl XLVIII, brought “scientists, biotech companies and professional athletes together, with the goal of building awareness and advancing scientific and medical opportunities for traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE) and concussions.” Forbes Contributor Nicole Fisher details the meeting of the minds that took place between “athletes and scientists to educate one another and discuss the real world of traumatic brain injury, concussions and memory loss.” Ms. Fisher’s full article is available here: http://www.forbes.com/sites/theapothecary/2014/02/05/nfl-players-kick-off-concussion-summit-super-bowl-week-despite-ongoing-litigations/.
About Amarantus BioScience Holdings, Inc.
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit http://www.amarantus.com/, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Leave a comment...